- Home
- ATXG vs QLGN Comparison
ATXG vs QLGN Comparison
Compare ATXG & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXG
- QLGN
- Stock Information
- Founded
- ATXG 2014
- QLGN 1996
- Country
- ATXG China
- QLGN United States
- Employees
- ATXG N/A
- QLGN N/A
- Industry
- ATXG Professional Services
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ATXG Consumer Discretionary
- QLGN Health Care
- Exchange
- ATXG Nasdaq
- QLGN Nasdaq
- Market Cap
- ATXG 3.8M
- QLGN 3.1M
- IPO Year
- ATXG N/A
- QLGN N/A
- Fundamental
- Price
- ATXG $0.55
- QLGN $1.69
- Analyst Decision
- ATXG
- QLGN
- Analyst Count
- ATXG 0
- QLGN 0
- Target Price
- ATXG N/A
- QLGN N/A
- AVG Volume (30 Days)
- ATXG 129.6K
- QLGN 43.3K
- Earning Date
- ATXG 08-14-2025
- QLGN 08-14-2025
- Dividend Yield
- ATXG N/A
- QLGN N/A
- EPS Growth
- ATXG N/A
- QLGN N/A
- EPS
- ATXG N/A
- QLGN N/A
- Revenue
- ATXG $4,310,835.00
- QLGN N/A
- Revenue This Year
- ATXG N/A
- QLGN N/A
- Revenue Next Year
- ATXG N/A
- QLGN N/A
- P/E Ratio
- ATXG N/A
- QLGN N/A
- Revenue Growth
- ATXG N/A
- QLGN N/A
- 52 Week Low
- ATXG $0.36
- QLGN $1.61
- 52 Week High
- ATXG $1.86
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- ATXG 53.61
- QLGN 29.57
- Support Level
- ATXG $0.44
- QLGN $1.66
- Resistance Level
- ATXG $0.58
- QLGN $1.87
- Average True Range (ATR)
- ATXG 0.05
- QLGN 0.10
- MACD
- ATXG 0.01
- QLGN 0.04
- Stochastic Oscillator
- ATXG 64.71
- QLGN 6.98
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.